Electrochemotherapy is a treatment combining a low dose of a chemotherapy drug and an electrical pulse (electroporation) applied directly to the cancer cells using an electrode.
This low level dose of chemotherapy drug is not normally effective against the cancer as it is difficult to get inside the cells. When the electric pulse is applied, the cells form pores allowing the drug to enter and be active against the cancer.
Basic concept of electrochemotherapy: (A) after injection drug surrounds the cells; (B) pores form on the cell membrane after pulse delivery, drug enters the cells (C); membrane resealing, drug entrapped inside the cells (D) drug causes irreversible damage to cancer cells that die from mitosis.
Electrochemotherapy is effective, well tolerated and can be performed after other treatments.
Electrochemotherapy reduces symptoms and improve quality of life for appropriately selected patients. As the chemotherapy drug is most active against the cancer cells, the normal tissue is unaffected.
The Cliniporator® and the Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumor nodules located to the skin, subcutaneous tissue, parenchyma and bone. The Cliniporator® and the Cliniporator® VITAE were developed and are commercialised by IGEA S.p.A. (Carpi, MO, Italy).
The Cliniporator® delivers the electric pulses trough multi-needles electrodes, for the electroporation of cutaneous, subcutaneous and mucosal lesions.
The Cliniporator® VITAE delivers the electric pulses through multi-needles electrodes, for the electroporation of cutaneous, subcutaneous and mucosal lesions and through individual needle electrodes, for the electroporation of bone and visceral lesions in a percutaneous and laparotomic setting.